Free Trial
NASDAQ:LSTA

Lisata Therapeutics (LSTA) Stock Price, News & Analysis

Lisata Therapeutics logo
$2.29 -0.04 (-1.72%)
Closing price 09/22/2025 04:00 PM Eastern
Extended Trading
$2.28 -0.02 (-0.66%)
As of 04:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lisata Therapeutics Stock (NASDAQ:LSTA)

Advanced

Key Stats

Today's Range
$2.14
$2.40
50-Day Range
$2.11
$2.96
52-Week Range
$1.87
$4.20
Volume
41,998 shs
Average Volume
20,571 shs
Market Capitalization
$20.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$23.50
Consensus Rating
Buy

Company Overview

Lisata Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
63rd Percentile Overall Score

LSTA MarketRank™: 

Lisata Therapeutics scored higher than 63% of companies evaluated by MarketBeat, and ranked 352nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lisata Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Lisata Therapeutics has a consensus price target of $23.50, representing about 926.2% upside from its current price of $2.29.

  • Amount of Analyst Coverage

    Lisata Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Lisata Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Lisata Therapeutics are expected to grow in the coming year, from ($2.66) to ($2.36) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lisata Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lisata Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lisata Therapeutics has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Lisata Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.17% of the float of Lisata Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lisata Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lisata Therapeutics has recently decreased by 27.04%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Lisata Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Lisata Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.17% of the float of Lisata Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lisata Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Lisata Therapeutics has recently decreased by 27.04%, indicating that investor sentiment is improving significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Lisata Therapeutics insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 9.10% of the stock of Lisata Therapeutics is held by insiders.

    • Percentage Held by Institutions

      Only 8.94% of the stock of Lisata Therapeutics is held by institutions.

    • Read more about Lisata Therapeutics' insider trading history.
    Receive LSTA Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Lisata Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

    By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

    LSTA Stock News Headlines

    Capital Gains Tax Strategies for Seniors
    Capital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.tc pixel
    See More Headlines

    LSTA Stock Analysis - Frequently Asked Questions

    Lisata Therapeutics' stock was trading at $2.98 on January 1st, 2025. Since then, LSTA shares have decreased by 23.2% and is now trading at $2.29.

    Lisata Therapeutics, Inc. (NASDAQ:LSTA) issued its earnings results on Thursday, August, 7th. The company reported ($0.54) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.11. The business earned $0.07 million during the quarter.
    Read the conference call transcript
    .

    Lisata Therapeutics' top institutional investors include BML Capital Management LLC (2.40%) and Cerity Partners LLC (0.14%).

    Shares of LSTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Lisata Therapeutics investors own include PayPal (PYPL), JD.com (JD), NIO (NIO), Construction Partners (ROAD), Sunrun (RUN), ASE Technology (ASX) and Coinbase Global (COIN).

    Company Calendar

    Last Earnings
    8/07/2025
    Today
    9/22/2025
    Next Earnings (Estimated)
    11/11/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - BIOMED/GENE
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:LSTA
    CIK
    320017
    Employees
    30
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $32.00
    Low Price Target
    $15.00
    Potential Upside/Downside
    +926.2%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    2 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    ($2.23)
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    -$19.99 million
    Net Margins
    N/A
    Pretax Margin
    -1,858.41%
    Return on Equity
    -69.68%
    Return on Assets
    -59.44%

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    5.77
    Quick Ratio
    5.77

    Sales & Book Value

    Annual Sales
    $1 million
    Price / Sales
    20.06
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $3.49 per share
    Price / Book
    0.66

    Miscellaneous

    Outstanding Shares
    8,760,000
    Free Float
    7,959,000
    Market Cap
    $20.06 million
    Optionable
    Not Optionable
    Beta
    1.01
    The Next 7 Blockbuster Stocks for Growth Investors Cover

    Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

    Get This Free Report

    This page (NASDAQ:LSTA) was last updated on 9/23/2025 by MarketBeat.com Staff
    From Our Partners